¼¼°èÀÇ Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ(CVC) ½ÃÀå
Central Line Catheters
»óǰÄÚµå : 1752909
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 474 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,496,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,489,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 38¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 28¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 5.5%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 38¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¸»ÃÊ »ðÀÔÇü Ä«Å×ÅÍ´Â CAGR 6.4%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 19¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À̽ÄÇü Æ÷Æ® Ä«Å×ÅÍ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 3.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ¾à 7¾ï 5,100¸¸ ´Þ·¯, Áß±¹Àº CAGR 8.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ(CVC) ½ÃÀåÀº 2024³â¿¡ 7¾ï 5,100¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 7¾ï 7,240¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 8.9%·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 2.7%¿Í 5.5%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.6%·Î ÃßÁ¤µË´Ï´Ù.

¼¼°èÀÇ Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ(CVC) ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÀÇ·á ÇöÀå¿¡¼­ Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ´Þ·¯, Áß±¹Àº CAGR ¼ö¿ä°¡ È®´ëµÇ°í ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ(CVC)´Â ƯÈ÷ ÁßȯÀÚ Ä¡·á, Á¾¾çÇÐ, Åõ¼®, Àå±â Åõ¾à µî Çö´ë ÀÇÇп¡¼­ ¾ø¾î¼­´Â ¾È µÉ ÇʼöÀûÀÎ µµ±¸°¡ µÇ¾ú½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¸¸¼ºÁúȯ, ƯÈ÷ ¾Ï, ½ÅÀåÁúȯ, ½ÉÇ÷°ü°è ÁúȯÀÌ ±ÞÁõÇϸ鼭 º´¿ø°ú ¿Ü·¡¿¡¼­ ÀÌ·¯ÇÑ Ä«Å×ÅÍÀÇ »ç¿ëÀÌ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Ä«Å×ÅÍ´Â ¾à¹°, ¼ö¾×, Ç÷¾×Á¦Á¦, ºñ°æ±¸ ¿µ¾çÁ¦ÀÇ È¿À²ÀûÀÎ Åõ¿©¸¦ °¡´ÉÇÏ°Ô Çϸç, Ç÷¿ªÇÐ ¸ð´ÏÅ͸µ ¹× Ç÷¾× »ùÇøµÀ» À§ÇÑ Á¢±Ù¼ºÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, Àå½Ã°£ »ðÀÔÀÌ °¡´ÉÇϱ⠶§¹®¿¡ ¹Ýº¹ÀûÀÎ ¹Ù´Ã »ðÀÔÀÇ Çʿ伺À» ÁÙ¿© ȯÀÚÀÇ Æí¾ÈÇÔ°ú ÀÓ»óÀû È¿À²¼ºÀÌ Çâ»óµË´Ï´Ù.

¼ö¼ú ¹× ÁßȯÀÚ½Ç ÀÔ¿ø Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡·Î ÀÎÇØ ½Å·Ú¼º°ú ³»±¸¼ºÀÌ ¶Ù¾î³­ Ç÷°ü Á¢±Ù ÀåÄ¡¿¡ ´ëÇÑ Çʿ伺ÀÌ ´õ¿í Ä¿Áö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºñ¿ë ¹× ȯÀÚ ¼±È£µµ Ãø¸é¿¡¼­ ¿Ü·¡ ȯÀÚ ¹× ÀçÅà ġ·á ¸ðµ¨·ÎÀÇ ÀüȯÀÌ ÁøÇàµÊ¿¡ µû¶ó ¾ÈÀüÇÏ°í »ç¿ëÇϱ⠽¬¿î Áß½ÉÁ¤¸Æ Á¢±Ù ½Ã½ºÅÛÀÇ Á߿伺ÀÌ ´õ¿í ºÎ°¢µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÓ»óÀû Çʿ伺°ú ÁøÈ­ÇÏ´Â ÀÇ·á ¼­ºñ½º Á¦°ø ÆÐ·¯´ÙÀÓÀÇ °áÇÕÀº Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ ±â¼úÀÇ ±¤¹üÀ§ÇÑ Ã¤Åðú Çõ½Å¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

Ä«Å×ÅÍ ¼³°è Çõ½ÅÀÌ ¾ÈÀü¼º°ú ¼º´ÉÀ» ¾î¶»°Ô Çâ»ó½Ã۰í Àִ°¡?

Ä«Å×ÅÍ Àç·á, ÄÚÆÃ ¹× »ðÀÔ ±â¼úÀÇ ¹ßÀüÀº Áß½ÉÁ¤¸Æ Ä«Å×ÅÍÀÇ »óȲÀ» º¯È­½Ã۰í ÀÖ½À´Ï´Ù. Á¦Á¶¾÷üµéÀº ÇöÀç Ä«Å×ÅÍ °ü·Ã Ç÷·ù °¨¿°(CLABSI)°ú Ç÷Àü¼º ÇÕº´Áõ ¹ß»ý·üÀ» ³·Ãß´Â Ç×±Õ ¹× Ç×Ç÷Àü ÄÚÆÃÀ» µµÀÔÇÏ¿© Ä«Å×ÅÍ Àå±â »ç¿ëÀ¸·Î ÀÎÇÑ °¡Àå ½É°¢ÇÑ À§Çè Áß µÎ °¡Áö¸¦ °¨¼Ò½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº º´¿øÀÌ º¸´Ù ¾ö°ÝÇÑ °¨¿° °ü¸® ±âÁØÀ» ÃæÁ·ÇÏ°í º´¿ø ³» °¨¿°°ú °ü·ÃµÈ ó¹úÀ» ÇÇÇϱâ À§ÇØ ³ë·ÂÇÏ´Â °¡¿îµ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÃֽŠīÅ×ÅÍ ¸ðµ¨Àº ³»¾Ð¼º ·ç¸à, ²¿ÀÓ ¹æÁö ¼³°è, ¿ª·ù ¹× °ø±â »öÀüÁõÀ» ¹æÁöÇÏ´Â ÀÏüÇü ¹ëºê¸¦ °®Ãß°í ÀÖ½À´Ï´Ù.

±â¼úÀû °³¼±Àº »ðÀÔ ¹× ¾È³» ±â¼ú¿¡µµ Àû¿ëµÇ¾ú½À´Ï´Ù. ÃÊÀ½ÆÄ À¯µµÇÏ¿¡ Ä«Å×ÅÍ »ðÀÔ ¹× ³»ºñ°ÔÀÌ¼Ç ±â´ÉÀ» °®Ãá ½Ã½ºÅÛÀÇ Ã¤ÅÃÀ¸·Î ù ¹øÂ° »ðÀÔ ¼º°ø·üÀÌ Çâ»óµÇ°í µ¿¸Æ õÀÚ ¹× ±âÈä°ú °°Àº ÇÕº´ÁõÀÌ °¨¼ÒÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¶¿µÁ¦¿Í ȣȯµÇ´Â µ¿·Â ÁÖÀÔ½Ä Ä«Å×ÅÍÀÇ °³¹ß·Î Ç÷°ü Á¢±ÙÀ» Ãß°¡ÇÏÁö ¾Ê°íµµ ¿µ»ó Áø´Ü¿¡ »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó ÇÕº´Áõ ¹ß»ý·üÀ» ³·Ãß°í ±â±âÀÇ ¼ö¸íÀ» ¿¬ÀåÇÏ¿© ÀÇ·áÁøÀÇ ºÎ´ãÀ» ÁÙ¿©ÁÝ´Ï´Ù.

¿Ö ±ÔÁ¦¿Í ÀÓ»ó ÇÁ·ÎÅäÄÝ Ç¥ÁØÈ­°¡ Á¡Á¡ ´õ Ȱ¹ßÇØÁö°í Àִ°¡?

Áß½ÉÁ¤¸Æ Ä«Å×ÅÍÀÇ »ç¿ëÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¾ÈÀü¼º, »ç¿ë ÇÁ·ÎÅäÄÝ ¹× À¯Áö°ü¸®¿¡ ´ëÇÑ °¨½Ã°¡ °­È­µÇ°í ÀÖÀ¸¸ç, FDA, EMA ¹× ¼¼°è °¨¿° °ü¸® ±â°ü°ú °°Àº ±ÔÁ¦ ´ç±¹Àº »ðÀÔ ÀýÂ÷, »ðÀÔ ÈÄ °ü¸® ¹× °¨¿° ¿¹¹æ °üÇàÀ» Ç¥ÁØÈ­Çϱâ À§ÇÑ ³ë·ÂÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. ¿©±â¿¡´Â ¹«±Õ À庮 Àû¿ë, ¼Òµ¶Á¦ »ç¿ë, µå·¹½Ì ±³Ã¼¿¡ ´ëÇÑ °¡À̵å¶óÀÎÀÌ Æ÷ÇԵǸç, ÀÌ´Â ¸ðµÎ CLABSI À§ÇèÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇÑ °ÍÀÔ´Ï´Ù. º´¿øÀº ¸ð¹ü »ç·Ê Áؼö¸¦ Çâ»ó½Ã۱â À§ÇØ Áß¾Ó ¶óÀÎ °ü·Ã ǰÁú °³¼± ÀÌ´Ï¼ÅÆ¼ºê¿Í ±³À° ÇÁ·Î±×·¥À» ½ÃÇàÇÏ¿© ´ëÀÀÇϰí ÀÖ½À´Ï´Ù.

Ç¥ÁØÈ­´Â ¶ÇÇÑ ÇÇÇÒ ¼ö ÀÖ´Â ÇÕº´Áõ¿¡ ´ëÇØ ÀÇ·á±â°ü¿¡ Æä³ÎƼ¸¦ ºÎ°úÇÏ´Â ÀÇ·á º¸»ó ü°è¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖÀ¸¸ç, È¿°úÀûÀÎ ÇÁ·ÎÅäÄÝÀ» µû¸£´Â °ÍÀÌ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¹è°æ¿¡¼­ Ä«Å×ÅÍ Ãë±ÞÀÇ ¸ðµç Ãø¸éÀ» ¾Æ¿ì¸£´Â Á¾ÇÕÀûÀÎ ÄÉ¾î ÆÐŰÁöÀÎ Áß½ÉÁ¤¸Æ°ü ¹øµéÀÌ ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ÀüÀÚ ÀÇ·á ±â·Ï(EHR)°ú µðÁöÅÐ ¸ð´ÏÅ͸µÀÇ º¸±ÞÀº Ä«Å×ÅÍ °ü·Ã µ¥ÀÌÅÍÀÇ ½Ç½Ã°£ °¡½Ã¼ºÀ» º¸ÀåÇÏ¿© ÄÄÇöóÀ̾𽺠¹× °á°ú ÃßÀû¿¡ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦ ¹× Á¦µµÀû ÈûÀ¸·Î ÀÎÇØ Àü ¼¼°èÀûÀ¸·Î Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ »ç¿ë¿¡ ´ëÇÑ º¸´Ù ÀϰüµÈ Áõ°Å ±â¹Ý ÇÁ·¹ÀÓ¿öÅ©°¡ Çü¼ºµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå È®´ëÀÇ ÁÖ¿ä ¿äÀÎÀº?

Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ(CVC) ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¾Ï, ½ÅºÎÀü, ÆÐÇ÷Áõ°ú °°Àº ¸¸¼º ÁúȯÀÌ Àü ¼¼°èÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó Àå±âÀûÀÎ Ç÷°ü Á¢±Ù ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÁßȯÀڽǰú Á¾¾çÇаúÀÇ È®Àå ¹× ³ëÀÎ Àα¸ Áõ°¡´Â Áß½ÉÁ¤¸Æ Á¢±Ù¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ±â¼ú Çõ½Å, ƯÈ÷ Ç×±Õ ÄÚÆÃ, ³»¾Ð¼º Àç·á ¹× ÷´Ü »ðÀÔ µµ±¸´Â ¾ÈÀü¼ºÀ» ³ôÀ̰í ÀÓ»óÀû ¿ëµµ¸¦ È®ÀåÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿Ü·¡ ȯÀÚ ¹× ÀçÅÃÄ¡·áÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ »ç¿ëÀÌ Æí¸®Çϰí ÈÞ´ë°¡ °£ÆíÇϸç À¯Áöº¸¼ö°¡ ÀûÀº Ä«Å×ÅÍ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Ç¥ÁØÈ­µÈ ÀǷḦ ÇâÇÑ ±ÔÁ¦ ¿òÁ÷ÀÓ°ú Ä«Å×ÅÍ °ü·Ã ÇÕº´ÁõÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇÑ °æÁ¦Àû Àμ¾Æ¼ºê´Â º´¿øµéÀÌ ´õ ³ôÀº ǰÁúÀÇ ±â±â¸¦ µµÀÔÇϵµ·Ï À¯µµÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÓ»óÀû, Àα¸Åë°èÇÐÀû, ±â¼úÀû Æ®·»µå°¡ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ¼±Áø±¹°ú ½ÅÈï±¹ ¸ðµÎ¿¡¼­ Áß½ÉÁ¤¸Æ Ä«Å×ÅÍ(CVC) ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç°(¸»ÃÊ »ðÀÔÇü Ä«Å×ÅÍ, À̽ÄÇü Æ÷Æ® Ä«Å×ÅÍ, ÅͳÎÇü Á¤¸Æ Ä«Å×ÅÍ, ºñÅͳÎÇü Á¤¸Æ Ä«Å×ÅÍ), µðÀÚÀÎ(½Ì±Û ·ç¸à µðÀÚÀÎ, ´õºí ·ç¸à µðÀÚÀÎ, ¸ÖƼ ·ç¸à µðÀÚÀÎ), Á¶¼º(Æú¸®¿ì·¹Åº Á¶¼º, Å×Ç÷РÁ¶¼º, ½Ç¸®ÄÜ °í¹« Á¶¼º), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ÃÖÁ¾»ç¿ëÀÚ, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 42°³»ç)

AI ÅëÇÕ

¿ì¸®´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Central Line Catheters Market to Reach US$3.8 Billion by 2030

The global market for Central Line Catheters estimated at US$2.8 Billion in the year 2024, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 5.5% over the analysis period 2024-2030. Peripherally Inserted Catheters, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Implanted Ports Catheters segment is estimated at 3.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$751.0 Million While China is Forecast to Grow at 8.9% CAGR

The Central Line Catheters market in the U.S. is estimated at US$751.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$772.4 Million by the year 2030 trailing a CAGR of 8.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Central Line Catheters Market - Key Trends & Drivers Summarized

Why Is Demand for Central Line Catheters Growing Across Healthcare Settings?

Central line catheters, also known as central venous catheters (CVCs), have become indispensable tools in modern medicine, especially in critical care, oncology, dialysis, and long-term medication administration. The global surge in chronic diseases-particularly cancer, kidney disorders, and cardiovascular conditions-has significantly increased the utilization of these catheters in hospitals and outpatient settings. They allow for the efficient administration of medications, fluids, blood products, and parenteral nutrition while providing access for hemodynamic monitoring and blood sampling. Their ability to remain in situ for extended periods also reduces the need for repeated needle insertions, improving patient comfort and clinical efficiency.

The rise in surgical procedures, intensive care admissions, and the growing geriatric population has further amplified the need for reliable and durable vascular access devices. Additionally, the increasing shift toward outpatient and home-based care models, driven by cost considerations and patient preference, has highlighted the importance of safe and easy-to-use central venous access systems. This combination of clinical necessity and evolving healthcare delivery paradigms is fueling widespread adoption and innovation in central line catheter technologies.

How Are Innovations in Catheter Design Enhancing Safety and Performance?

Advances in catheter materials, coatings, and insertion techniques are transforming the central line catheter landscape. Manufacturers are now introducing antimicrobial and antithrombogenic coatings to reduce the incidence of catheter-associated bloodstream infections (CLABSIs) and thrombotic complications-two of the most significant risks associated with long-term catheter use. These innovations are proving crucial as hospitals seek to meet stricter infection control benchmarks and avoid penalties tied to hospital-acquired infections. Newer catheter models feature pressure-resistant lumens, kink-resistant designs, and integrated valves to prevent backflow and air embolisms.

Technological improvements are also being applied to insertion and guidance techniques. The adoption of ultrasound-guided catheter placement and the use of navigation-enhanced systems are improving first-attempt success rates and reducing complications such as arterial puncture or pneumothorax. Furthermore, the development of power-injectable catheters compatible with contrast media is enabling their use in diagnostic imaging without the need for additional vascular access. These innovations not only improve patient outcomes but also reduce the burden on healthcare providers by lowering complication rates and extending device longevity.

Why Is Regulation and Clinical Protocol Standardization Gaining Momentum?

As the use of central line catheters grows, so too does the scrutiny surrounding their safety, usage protocols, and maintenance. Regulatory authorities such as the FDA, EMA, and global infection control organizations have intensified efforts to standardize insertion techniques, post-placement care, and infection prevention practices. This includes guidelines around sterile barrier precautions, antiseptic use, and dressing changes-all aimed at minimizing CLABSI risk. Hospitals are responding by implementing central line-associated quality improvement initiatives and training programs to improve adherence to best practices.

Standardization is also being driven by reimbursement structures that penalize healthcare facilities for avoidable complications, making it imperative to follow validated protocols. This push has led to the rise of central line bundles-comprehensive care packages that cover all aspects of catheter handling. The increased use of electronic health records (EHRs) and digital monitoring is helping track compliance and outcomes, ensuring real-time visibility into catheter-related data. These regulatory and institutional forces are shaping a more consistent, evidence-based framework for central line catheter use globally.

What Are the Key Factors Powering Market Expansion?

The growth in the central line catheters market is driven by several factors. A rising global burden of chronic diseases, such as cancer, renal failure, and sepsis, is increasing the reliance on long-term vascular access solutions. The expansion of intensive care units and oncology departments, combined with a growing elderly population, is further escalating demand for central line access. Technological innovations-particularly antimicrobial coatings, pressure-resistant materials, and advanced insertion tools-are enhancing safety and expanding clinical applications. Additionally, the trend toward outpatient and home healthcare is creating demand for user-friendly, portable, and low-maintenance catheters. Regulatory momentum toward standardized care and the financial incentives for minimizing catheter-related complications are pushing hospitals to adopt higher-quality devices. These intersecting clinical, demographic, and technological trends are fueling sustained growth in the central line catheter market across both developed and emerging healthcare systems.

SCOPE OF STUDY:

The report analyzes the Central Line Catheters market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Peripherally Inserted Catheters, Implanted Ports Catheters, Tunneled Venous Catheters, Non-Tunneled Venous Catheters); Design (Single Lumen Design, Double Lumen Design, Multiple Lumen Design); Composition (Polyurethane Composition, Teflon Composition, Silicone Rubber Composition); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â